2
Clinical Trials associated with MIDRIX-CTRL DCs(University Ghent)Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung Cancer
MIDRIXNEO-LUNG is a novel autologous dendritic cell vaccine for non-small cell lung cancer patients, targeting neoantigens predicted from the patient-individual tumor's mutanome. This first-in-human study aims to primarily establish maximal tolerated dose of MIDRIXNEO-LUNG administered i.v.
Phase Ia Study of MIDRIX4-LUNG, a Tetravalent Autologous Dendritic Cell Vaccine, in Patients With Metastatic Non-small Cell Lung Cancer
MIDRIX4-LUNG is a novel tetravalent autologous dendritic cell vaccine in metastatic non-small cell lung cancer patients. This first-in-human study aims to primarily establish maximal tolerated dose of MIDRIX4-LUNG administered i.v.
100 Clinical Results associated with MIDRIX-CTRL DCs(University Ghent)
100 Translational Medicine associated with MIDRIX-CTRL DCs(University Ghent)
100 Patents (Medical) associated with MIDRIX-CTRL DCs(University Ghent)
100 Deals associated with MIDRIX-CTRL DCs(University Ghent)